Kinarus Therapeutics Holding AG
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kinarus Therapeutics Holding AG generated cash of -$359,000, which is more than the previous year. Cash used in financing activities reached the amount of $420,000 last year. Net change in cash is therefore $61,000.
Cash Flow
| 2012 | 648K | -41K | 0 |
|---|---|---|---|
| 2013 | -1.68M | -330K | -21K |
| 2014 | -118K | 50K | -32K |
| 2015 | -125K | 66K | -32K |
| 2016 | -77K | 120K | -28K |
| 2017 | 124K | 207K | 182K |
| 2018 | -749K | -4K | 181K |
| 2019 | -662K | 0 | 607K |
| 2020 | -378K | -899K | 523K |
| 2021 | -359K | 0 | 420K |
PRFN.SW Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 63K | 880K | 943K | 1.54M | 975K | 1.11M | 1.21M | 1.29M | 3.32M | 2.69M |
Operating activities | ||||||||||
Net income | -143K | -7K | -940K | -762K | -260K | -1.01M | -1.63M | -865K | -2.98M | -403K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 6K | 25K | 24K | 89K | 217K | 231K | 242K | 377K | 1.39M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -359K | -378K | -662K | -749K | 124K | -77K | -125K | -118K | -1.68M | 648K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -4K | -13K | -8K | -5K | -18K | -8K | -109K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | -899K | 0 | -4K | 207K | 120K | 66K | 50K | -330K | -41K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 39K | 206K | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -6K | 0 | -23K | 0 | -20K | 0 | -22K | -21K | 0 |
Cash used in financing activities | 420K | 523K | 607K | 181K | 182K | -28K | -32K | -32K | -21K | 0 |
Net Change In Cash | 61K | -817K | -63K | -606K | 574K | -138K | -100K | -80K | -2.02M | 627K |
Cash at end of period | 124K | 63K | 880K | 943K | 1.54M | 975K | 1.11M | 1.21M | 1.29M | 3.32M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |